Coronavirus (COVID-19), Coagulation, and Exercise: Interactions That May Influence Health Outcomes

Emma Kate Zadow, BSc, Hons, PhD1  Daniel William Taylor Wundersitz, BESSc, Hons, PhD1
Diane Louise Hughes, BSc, Hons, PhD1,2  Murray John Adams, BSc, Hons, PhD3
Michael Ian Charles Kingsley, BPhEd, MSc, PhD1,4  Hilary Anne Blacklock, MB ChB5
Sam Shi Xuan Wu, BSc, MSc, PhD6  Amanda Clare Benson, BEd(Phys. Ed), MSc, PhD6
Frédéric Dutheil, MD, PhD7  Brett Ashley Gordon, BAppSc, MAppSc, PhD1

1 Holsworth Research Initiative, La Trobe Rural Health School, La Trobe University, Bendigo, Victoria, Australia
2 Department of Pharmacy and Biomedical Sciences, School of Molecular Sciences, La Trobe University, Bendigo, Victoria, Australia
3 College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Western Australia, Australia
4 Department of Exercise Sciences, University of Auckland, Auckland, New Zealand
5 Department of Haematology, Middlemore Hospital, Auckland, New Zealand
6 Department of Health and Medical Sciences, Swinburne University of Technology, Hawthorn, Victoria, Australia
7 Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, Clermont-Ferrand, France

Address for correspondence: Emma Kate Zadow, BSc (Hons), PhD, Holsworth Research Initiative, La Trobe Rural Health School, La Trobe University, Edwards Road, Flora Hill, Bendigo, Victoria 3550, Australia (e-mail: e.zadow@latrobe.edu.au).

Abstract

The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortality in people with COVID-19 and is partially reflected by enhanced D-dimer levels. Poor vascular health, which is associated with the cardiometabolic health conditions frequently reported in people with severer forms of COVID-19, might exacerbate the risk of coagulopathy and mortality. Sedentary lifestyles might also contribute to the development of coagulopathy, and physical activity participation has been inherently lowered due to at-home regulations established to slow the spread of this highly infectious disease. It is possible that COVID-19, coagulation, and reduced physical activity may contribute to generate a “perfect storm,” where each fuels the other and potentially increases mortality risk. Several pharmaceutical agents are being explored to treat COVID-19, but potential negative consequences are associated with their use. Exercise is known to mitigate many of the identified side effects from the pharmaceutical agents being trialled but has not yet been considered as part of management for COVID-19. From the limited available evidence in people with cardiometabolic health...
COVID-19 and Coagulopathy

It has been reported that up to 68% of people diagnosed with COVID-19 and needing intensive care have preexisting comorbidities known to affect the vascular system, including hypertension, cardiovascular disease, hypercholesterolemia, and diabetes. These conditions typically stem from, or contribute to, the metabolic syndrome, which is associated with increased amounts of visceral adipose tissue. This tissue is known to secrete several cytokines that are implicated in the inflammatory cascade, leading to a state of low-grade inflammation. Reports on clinical characteristics of COVID-19 intensive care patients include elevated cytokine levels such as interleukin (IL)-2, IL-7, IL-10, granulocyte colony-stimulating factor, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP1), macrophage inflammatory protein-1 α (MIP1α), and tumor necrosis factor-α (TNFα). Activation of these cytokines can result in an inflammatory cascade, leading to coagulation activation and endothelial dysfunction.

Elevated levels of proinflammatory cytokines might partially explain the large number of COVID-19 infected individuals presenting with coagulopathy, in particular elevated D-dimers, fibrinogen degradation products (FDPs), and abnormal activated partial thromboplastin time. Elevations in these coagulopathy parameters and impaired fibrinolysis are significantly related to poor prognosis in COVID-19. For example, Zhou et al. reported that 68% of patients presenting with COVID-19 had increased activation of coagulation as indicated by elevated D-dimer concentration at presentation (>500 ng/mL). Most importantly, Zhou et al. reported that D-dimer concentrations >1,000 ng/mL were associated with an eightfold increased odds of fatal outcome, suggesting coagulopathy to be a predictor of mortality risk in individuals with COVID-19.

D-dimer is a widely used clinical biomarker of endogenous fibrin clot formation and a well-recognized laboratory marker of hypercoagulability (coagulation activation). Elevated D-dimer levels in people with COVID-19 are associated with a higher risk of intensive care unit admission or death. The mortality risk associated with higher levels of D-dimer is particularly evident in older people and those with cardiometabolic comorbidities. In addition to elevated D-dimer levels, Tang et al. reported significantly higher levels of FDPs and
prolonged prothrombin time (PT) in COVID-19 nonsurvivors compared with those who survived. Therefore, it can be suggested that these conventional parameters of coagulation are significantly associated with overall prognosis.

**Physical Activity and Risk for Coagulopathy**

A common behavioral feature, and risk factor, for the comorbidities associated with COVID-19 is insufficient physical activity. A diagnosis of COVID-19, whether mild or severe symptoms occur, is likely to reduce physical activity even further in those required to isolate in the home environment or be bedbound in a hospital setting. While underinstructions to self-isolate indoors to slow the outbreak of COVID-19, data obtained by smartwatches have demonstrated that weekly physical activity has decreased by 9% to 48%. This reduction in physical activity is frequently associated with venous thromboembolism, which typically consists of pulmonary embolism or deep vein thrombosis. These major clinical problems negatively alter blood coagulability and have potential life-threatening consequences, such as acute cardiac injury and/or sudden death. Therefore, it may be that COVID-19, coagulation, and reduced physical activity contribute to generate a "perfect storm," where each fuels the other and potentially increases mortality risk. Physical activity can induce many health benefits and can positively modify coagulation markers in healthy populations. High cardiovascular fitness has been suggested to offer some protection against the deleterious effects of COVID-19 and consequently it is important to safely participate in physical activity during this pandemic. Therefore, early intervention through physical activity or exercise might mitigate negative health consequences and reduce mortality risk in people with mild or moderate COVID-19. However, at this point, it is not clear if, or how, physical activity or exercise can be used as part of the overall treatment process for coagulopathy associated with COVID-19.

**Exercise and Hemostasis**

Exercise (planned physical activity completed specifically for the purpose of improving health and fitness) has been demonstrated to have considerable effects on hemostasis by positively modifying markers of coagulation and fibrinolytic response in apparently healthy populations. Low- to moderate-intensity exercise is likely to reduce the risk of coagulopathy; however, acute bouts of high-intensity exercise may act as a potential trigger for increased thrombotic risk due to an increase in venous blood flow, blood viscosity, and laminar shear stress, activating the coagulation system. Nonetheless, the influence of acute bouts of exercise on coagulation and fibrinolysis have often produced conflicting data due to various factors including varying study protocols and exercise modes. It is evident that exercise intensity plays an influential role in shifting the equilibrium between coagulation and fibrinolysis, with strenuous (high-intensity) exercise consistently demonstrated to increase hemostatic activation as opposed to low- to moderate-intensity exercise.

For apparently healthy individuals, exercise completed at a higher intensity appears to increase clot degradation, probably in response to coagulation activity. This is evidenced by an increase in overall fibrinolytic activity when cycling at 70% VO2 max compared with 40% VO2 max but also an approximately 50% increase in t-PA activity when cycling at 80% VO2 max compared with 50% VO2 max. Furthermore, Menzel and Hilberg observed increased thrombin–antithrombin complexes when cycling at 100% but not at 80% individual anaerobic threshold. These findings indicate that exercise intensity is an important contributor to thrombin generation through activation of both the coagulation and fibrinolytic systems, albeit in a healthy population, and it is clear that to minimize the risk of coagulopathy, moderate- to high-intensity exercise should be avoided by untrained, inappropriately trained, or sedentary individuals. Despite this, there remains an opportunity to explore the use of exercise as an adjuvant therapeutic tool in the management and prevention of COVID-19-associated coagulopathy.

Separate to acute responses to exercise, individuals who are regularly physically active possess a "thromboprotective element," whereas individuals who are not regularly active or those with a preexisting medical condition have attenuated fibrinolytic responses in combination with exaggerated changes in procoagulant and platelet variables. When investigating coagulation and fibrinolytic responses in relation to exercise in physically inactive individuals and those with varying medical conditions (i.e., peripheral arterial disease, metabolic syndrome, hemiparetic strokes, and hypertension), exercise intensity varied between 50% and 70% VO2 max. Exercise performed at 50% VO2 max increased fibrinolytic activity in both active and inactive apparently healthy males, but larger increases in t-PA were observed only in physically inactive males. In sedentary males with metabolic syndrome, exercise at 70% VO2 max reduced fibrinolytic activity and these individuals remained hypofibrinolytic compared with non-obese sedentary males. In middle-aged females with previous myocardial infarction, Eriksson-Berg et al demonstrated increased fibrinolytic activity following exercise at 50% maximal work capacity, whereas markers of coagulation activation remained undisrupted. Low- to moderate-intensity exercise in people with varying medical conditions increases fibrinolytic activity, as evidenced by elevated t-PA concentrations, which may persist up to 1 hour postexercise. Therefore, even for individuals with existing cardiometabolic health conditions associated with worse COVID-19 outcomes, lower intensity exercise may have thromboprotective effects. It is then possible that low- to moderate-intensity exercise may increase acute fibrinolytic activity and reduce COVID-19-associated blood clot formation. However, to date, no studies have investigated how exercise might impact the hemostatic profile within this population.

**COVID-19, Pharmaceutical Agents, and Exercise**

No universal pharmaceutical treatment for COVID-19 is as yet available, although multiple therapeutic strategies are
being attempted and trialled.\textsuperscript{15,16,88–91} These relate to pharmaceutical agents that (1) block viral entry to host cells through the prevention of attachment or fusion, or removal of virus by immune cells, or the use of hyperimmune plasma, (2) block viral replication and survival in host cells through viral protease inhibition or viral nucleic acid and protein synthesis inhibition, (3) dampen the exaggerated immune response through corticosteroids, cytokine blockade, or intravenous immunoglobulin, and/or (4) inhibit the abnormal prothrombotic response by anticoagulants.\textsuperscript{88,92}

Due to the broad range of pharmaceutical agents being trialled for COVID-19, and the apparent impact of the virus on hematological parameters that are associated with poor prognosis and mortality,\textsuperscript{13} it is critical to examine the possible pharmaceutical agent interactions with exercise. Table 1 indicates the broad class of pharmaceutical agents being trialled for COVID-19,\textsuperscript{15,16} potential consequences associated with their use, and implications for exercise.

**Table 1** Classes of pharmaceutical agents being trialled for COVID-19, intended action, potential side effects associated with their use, and considerations for exercise

<table>
<thead>
<tr>
<th>Pharmaceutical class</th>
<th>Intended action</th>
<th>Potential side effects/interactions</th>
<th>Consideration for exercise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulants</td>
<td>Suppression of synthesis/function of various clotting factors to prevent the formation of blood clots</td>
<td>Hemorrhage, Thrombocytopenia, Hypersensitivity reactions, Adverse interactions with other drugs that bind to plasma proteins or are metabolized by the liver</td>
<td>↑ Blood fluidity &amp; blood flow, ↓ oxygen delivery. Exercise induced hypotension</td>
</tr>
<tr>
<td>Antiviral agents</td>
<td>Blocks viral entry to host cells • Serine protease inhibitors Blocks viral replication in host cells Inhibits angiotensin-converting enzyme 2</td>
<td>Joint and/or muscle pain, Headaches, dizziness, nausea, Cough, nasal congestion, fever, body aches, malaise, and, in severe cases, death</td>
<td>J-shaped hypothesis for exercise dose and infection risk. ↓ Proprioception due to neuropathy &amp; ↓ muscle control due to myopathy and muscle weakness.</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Regulates gene expression to suppress inflammation and immune responses</td>
<td>Can ↑ risk and severity of infections, as well as masking infections, May cause elevated blood glucose levels, fluid retention, or elevated blood pressure Long-term use may suppress the immune system, May ↑ gastrointestinal symptoms, Can ↓ bone density, cause osteoporosis, and ↓ risk of fractures, Affects metabolism fat deposition Impaired ability to sleep Mood changes (&gt;30 mg/day) Eye problems Atherosclerosis and aseptic necrosis (long-term use and high doses) Withdrawal can cause fatigue, joint pain, muscle stiffness and tenderness, or fever</td>
<td>&gt; 2 wk use ↓ ability of the body to respond to physical stress. Muscle weakness in people who may already be strength compromised. Potential for impaired physiological response to exercise due to adrenal gland dysfunction. Potential for impaired neural signaling, muscle damage, and muscle weakness.</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory</td>
<td>Inhibits COX-1 or COX-2 enzymes, thus stopping prostaglandin production Blocks toll-like receptors involved in cytokine production</td>
<td>Gastrointestinal irritation, fluid retention, and elevated blood pressure ↑ Risk heart attack and stroke, dizziness, light-headedness, tiredness, headache, ringing in the ears</td>
<td>During prolonged exercise, they may strain the kidneys and ↓ the ability of the muscle to recover. ↑ Exacerbate risk of injury as it masks musculoskeletal pain. ↑ Blood pressure response with exercise, particularly with higher intensities. ↓ Capacity for skeletal muscle oxygen transfer ↓ energy availability.</td>
</tr>
<tr>
<td>Disease-modifying antirheumatoid drugs</td>
<td>Antimalarial • Destruction of parasite</td>
<td>May be immunosuppressive, myelosuppressive, cause cardiac toxicity, or severe low blood glucose levels</td>
<td>Myelosuppressive side effects could impair exercise capacity. Reliance on aerobic energy metabolism. Additional thermoregulation required.</td>
</tr>
</tbody>
</table>

Notes: ↑ increased; ↓ reduced/decreased. Intended action and potential side effects information obtained from the Australian Medicines Handbook (https://amhonline.amh.net.au/auth). This table is a general review only and is not specific to individual drugs. For a more empiric or investigational use of individualized agents with antithrombotic properties in COVID-19, please see the review by Bikdeli et al.\textsuperscript{15}
Antiviral agents previously used to treat influenza have been reported to be effective for treating COVID-19. When these have been used in combination with immune system pharmaceuticals (i.e., antimalarial and protease inhibitors), symptoms have been alleviated, along with reduced viral shedding and hospital stay. Recognized side effects of antiviral agents include fatigue, dizziness, and poor mental health. Antimalarial agents have some common side effects with antiviral drugs, including dizziness and mental health issues along with other exercise prescription considerations such as muscle weakness, cardiac arrhythmia, and heart failure. Protease inhibitors also have the potential to induce cardiac arrhythmia and reduce metabolic control. Therefore, the use of exercise as an adjuvant therapy might be appropriate given the positive effects of exercise on all of the potential adverse reactions to the pharmaceutical agents (i.e., enhanced mood/mental health, cardiovascular and metabolic health), along with the strong potential of low- to moderate-intensity exercise to directly affect the coagulation process. However, the setting and mode for exercise delivery needs to be carefully selected, thus avoiding the potential consequences of exacerbating symptoms of dizziness and the potential for falling and further injury.

**Conclusion**

The association of abnormal coagulation with severe pneumonia and death in people with COVID-19 has led to reports on thromboembolic complications. This seems to be more apparent in people who also have cardiometabolic health conditions. Particularly in people who have mild or moderate symptoms of COVID-19, and perhaps those with more severe COVID-19, low- to moderate-intensity exercise could be regarded as adjuvant therapy to assist with minimizing the potential adverse reactions of the infection and any treatment-related issues. Furthermore, low- to moderate-intensity exercise might be important to contribute to reducing the risk of developing more severe forms of COVID-19 and further reducing the risk of coagulopathy that seems to be associated with mortality. Yet, enhanced social distancing (i.e., at least 2 m) while practicing outdoor sport and exercise would be mandatory since airborne virus propagation is considerably higher during physical exercise.

**Conflict of Interest**

None.

**References**

27. Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis...
COVID-19, Coagulopathy, and Exercise  


Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity (Silver Spring) 2020(Apr):23


Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity (Silver Spring) 2020(Apr):23


Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity (Silver Spring) 2020(Apr):23

69 Gram AS, Petersen M, Quist JS, Rosenkilde M, Stalnkleht B, Bladbjerg EM. Effects of 6 months of active commuting and leisure-time exercise on fibrin turnover in sedentary individuals with overweight and obesity: a randomised controlled trial. J Obes 2018;2018:7140754
70 Braschi A. Acute exercise-induced changes in hemostatic and fibrinolytic properties: analogies, similarities, and differences between normotensive subjects and patients with essential hypertension. Platelets 2019;30(06):675–689
89 Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol 2020;83:104327
100 Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000;15(Suppl):E156–E163


